Cases and resources in vascular techniques
This section provides a selection of cases and resources provided by experts in vascular techniques.
Dr. Daniela Branzan highlights that effective spinal cord ischemia prevention in thoracoabdominal repair relies on identifying risk factors, staging the procedure, maintaining permissive hypertension, and ensuring close postoperative monitoring.
Prof. Peter Schneider puts BEST-CLI into perspective: bypass benefits a selected CLTI subgroup, while endovascular remains the mainstay in real-world practice.
A stepwise strategy combining rotational thrombectomy and DCB angioplasty achieves high patency rates and a favourable safety profile in complex femoropopliteal ISR.
A multi-institutional study validates the SVS Appropriate Use Criteria for intermittent claudication, showing that many revascularisations may be inappropriate, especially in patients with mild or moderate lifestyle limitations. Inappropriate procedures were linked to more reinterventions and major amputations, highlighting the AUC’s potential to reduce overuse and improve outcomes.
Discover the latest clinical evidence and real-world insights on VBX Stent Grafts in complex EVAR.
Dr. Sukgu Han discusses why renal artery target vessel patency is a key challenge in endovascular TAAA repair and explores strategies—from antiplatelet therapy to bridging stent design—that may improve long-term outcomes.
At PVI 2025, Prof. Saratzis weighs in on a tough SFA CTO scenario: endovascular procedure or another route? A one-minute insight that might change how you think about these cases.
This multicentre ALIVE Registry analysis compares endovascular, hybrid, and open surgical revascularisation strategies in acute lower limb ischaemia. Endovascular treatment was associated with lower risks of major amputation and comparable survival at 3 years, supporting its role as a first-line approach in selected patients.
The management of aortic arch pathology is frequently demanding and poses significant anatomical challenges, ranging from open surgery to hybrid debranching procedures and, ultimately, total endovascular approaches.
Which drug-coated balloon is better for femoropopliteal artery disease: sirolimus or paclitaxel? The SIRONA trial compared both at 12 months, looking at vessel patency and key clinical outcomes.
Discover how sirolimus-coated balloons stack up as a safe and effective alternative to paclitaxel!
